Evaluation of Interferon-Gamma in Patients with Type 2 Diabetes and Colorectal Cancer

2015 ◽  
Vol 07 (01) ◽  
Author(s):  
I Bosek ◽  
R Kuczerowski
2021 ◽  
Vol 32 ◽  
pp. S125-S126
Author(s):  
G. Calderillo-Ruiz ◽  
C. Diaz ◽  
H. Lopez Basave ◽  
E. Ruiz-Garcia ◽  
A. Apodaca ◽  
...  

2021 ◽  
Vol 160 (6) ◽  
pp. S-30
Author(s):  
Frederikke Sch⊘nfeldt Troelsen ◽  
Henrik Toft S⊘rensen ◽  
Lars Pedersen ◽  
Rune Erichsen

2018 ◽  
Vol 11 (2) ◽  
pp. 535-541 ◽  
Author(s):  
Yu-Tang Chang ◽  
Hsiang-Lin Tsai ◽  
Ya-Ting Kung ◽  
Yung-Sung Yeh ◽  
Ching-Wen Huang ◽  
...  

2019 ◽  
Vol 156 (6) ◽  
pp. S-676-S-677
Author(s):  
Joanne P. Young ◽  
Erin L. Symonds ◽  
David Jesudason ◽  
Nicola Poplawski ◽  
Andrew Ruszkiewicz ◽  
...  

QJM ◽  
2019 ◽  
Author(s):  
C-H Chen ◽  
C-L Lin ◽  
C-Y Hsu ◽  
C-H Kao

Abstract Background Identifying colorectal cancer associated risks is important for conducting a program for the survey and prevention of colorectal cancer. Aim To investigate the association between use of insulin or metformin with colorectal cancer (CRC) in type 2 diabetes (T2DM). Design Population-based cohort study. Methods Through analysis of National Health Insurance (NHI) database between 1998 and 2010 in Taiwan, we identified 66 324 T2DM patients aged ≥ 20 years and selected subjects without diabetes by 1: 1 randomly matching with the study cohort based on age, sex and index date. We followed up the participants until 31 December 2011 or when they withdrew from the NHI program. Results Compared with non-diabetic subjects, the T2DM patients exhibited an increased risk of CRC [adjusted HR (aHR) = 1.56, 95% confidence interval (CI) = 1.39–1.75], after adjustment for age, sex, urbanization level, comorbidities and examinations of colonoscopy, sigmoidoscopy, or stool occult blood test. Among the T2DM patients, insulin usage increased the risk of CRC (aHR = 1.86, 95% CI = 1.58–0–2.19) after adjustment for age, sex, urbanization level, comorbidities, metformin usage and examinations; nevertheless, metformin decreased the risk of CRC (aHR = 0.65, 95% CI = 0.54–0.77) after adjustment for age, sex, urbanization level, comorbidities, insulin usage and examinations. Compared with the non-insulin cohort, the risk of CRC tended to increase with the incremental dosage of insulin exposure. Conclusion Our population-based cohort study demonstrated an association between T2DM and CRC. Among the T2DM patients, insulin use was associated with an increased risk of CRC and metformin use was associated with a decreased risk of CRC. Inability to obtain information on several potential confounding factors, such as lifestyle and dietary habits, is the major limitation of the study.


Diabetes Care ◽  
2014 ◽  
Vol 38 (3) ◽  
pp. 495-502 ◽  
Author(s):  
Paul J.H.L. Peeters ◽  
Marloes T. Bazelier ◽  
Hubert G.M. Leufkens ◽  
Frank de Vries ◽  
Marie L. De Bruin

2016 ◽  
Vol 6 ◽  
Author(s):  
Valentina Rosato ◽  
Alessandra Tavani ◽  
Esther Gracia-Lavedan ◽  
Elisabet Guinó ◽  
Gemma Castaño-Vinyals ◽  
...  

2018 ◽  
Vol 21 ◽  
pp. S123-S124
Author(s):  
J.A. Overbeek ◽  
J.G. Kuiper ◽  
A.A. van der Heijden ◽  
M. Labots ◽  
U. Haug ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document